PURE Bioscience, Inc.
PURE
$0.08
$0.0228.21%
OTC PK
| 04/30/2026 | 01/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 13.96% | -37.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.96% | -37.29% | |||
| Cost of Revenue | 15.05% | -20.16% | |||
| Gross Profit | 13.03% | -47.11% | |||
| SG&A Expenses | -16.41% | 14.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.14% | 3.68% | |||
| Operating Income | 24.16% | -80.21% | |||
| Income Before Tax | 20.51% | -69.18% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 20.51% | -69.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.51% | -69.18% | |||
| EBIT | 24.16% | -80.21% | |||
| EBITDA | 24.05% | -80.42% | |||
| EPS Basic | 20.00% | -70.73% | |||
| Normalized Basic EPS | 20.45% | -69.23% | |||
| EPS Diluted | 20.00% | -70.73% | |||
| Normalized Diluted EPS | 20.45% | -69.23% | |||
| Average Basic Shares Outstanding | -0.94% | 0.00% | |||
| Average Diluted Shares Outstanding | -0.94% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||